Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-NETA
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
alpha-NETA (2-(alpha-naphthoyl)ethyltrimethylammonium iodide) is a synthetic small molecule that acts as a potent, non-competitive inhibitor of choline acetyltransferase (ChAT) and a potent antagonist of chemokine-like receptor 1 (CMKLR1, also known as ChemR23). Additionally, it has been identified as an agonist of trace amine-associated receptor 5 (TAAR5) and an antagonist of aldehyde dehydrogenase 1 family member A1 (ALDH1A1). alpha-NETA is widely utilized as a research-use-only tool compound to investigate cholinergic transmission, chemerin/CMKLR1 signaling, and TAAR5 biology in preclinical models of inflammatory diseases, metabolic disorders, and various cancers.
- Other names
- 2-(alpha-naphthoyl)ethyltrimethylammonium iodidea-NETAaNETAα-NETA
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)CMKLR1 (Chemokine-like receptor 1)CHAT (Choline acetyltransferase)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on alpha-NETA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-NETA.